Prescription Digital Therapeutics in Schizophrenia: A Managed Care Perspective on Advancements

This activity includes a social worker perspective video interview.

Program Description
Many patients with schizophrenia struggle with debilitating residual symptoms, treatment-related adverse effects, and difficulty with adherence to therapy as schizophrenia requires lifelong management, even when symptoms are not evident. Traditional treatment options for schizophrenia might require frequent in-person visits, which can increase treatment burden for patients or pose access barriers. Prescription digital therapeutics (PDTs) are emerging as a powerful tool for mental health conditions. This article will explore their potential use particularly in schizophrenia to alleviate negative symptoms, as well as in reducing the clinical and socioeconomic burden of the disorder. Managed care professionals should recognize the opportunity for PDTs to bridge gaps in care as a complementary tool by improving access to individualized and effective care. Yet, there remain challenges to PDTs, such as long-term patient utilization, establishing pathways for insurance coverage for digital interventions, and clinical practice guidance. This supplement reviews current treatments for psychotic (positive), negative, and cognitive symptoms and advantages and challenges in the use of emerging PDTs in schizophrenia care paradigms. A social worker perspective interview accompanies this supplement and highlights opportunities for care coordination, helping patients navigate the health care system, and providing other services and support to empower patients with schizophrenia to manage their illness and improve their quality of life.

Target Audience: Managed care pharmacists

Type of Activity: Application
Release date: September 23, 2024
Expiration date: September 23, 2025
Learner level: Foundational
Time to complete activity: 2.0 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Distinguish the characteristics of negative and cognitive symptoms associated with schizophrenia.
• Explore the burden and treatment challenges of schizophrenia.
• Examine the clinical data supporting the efficacy and safety of prescription digital therapeutics (PDTs) that target unmet needs in the management of schizophrenia.
• Illustrate opportunities for managed care pharmacists to mitigate the clinical and economic impact of schizophrenia while enhancing access to emerging PDTs to alleviate negative and cognitive symptoms.

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-24-231-H01-P. The activity is available for CE credit through September 23, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Nidal Moukaddam, MD, PhD, has the following relevant financial relationships with commercial interests to disclose:
Grant/Research Support: National Institute on Drug Abuse R01 SAMHSA grant (federal funding), Tonix Pharmaceuticals Holding Corp, Relmada Therapeutics, Inc

Timothy D Aungst, PhamD, has the following relevant financial relationships with commercial interests to disclose:

Consultant: Otsuka, GoodRx

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Medical Writing and Editorial Support

Monica Shah, PharmD; and Anne Schock Erlich, PharmD, have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta, and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms